Substance use ‐ relapse · co‐occurring depression and substance use disorders
It is very uncertain whether interpersonal Psychotherapy for Depression (IPT‐D) changes substance use ‐ relapse compared with other Psychological Interventions (very low certainty).
1 finding from 1 review
Retention in treatment · co‐occurring depression and substance use disorders
It is very uncertain whether interpersonal Psychotherapy for Depression (IPT‐D) changes treatment retention compared with other Psychological Interventions (very low certainty).
1 finding from 1 review
Percent of days abstinent · co‐occurring depression and substance use disorders
1 finding from 1 review
Depression score · co‐occurring depression and substance use disorders
2 findings from 1 review
Intervention not reported
Severity of depression dichotomous measures ‐ Tricyclics versus placebo: "very much" or "much" improvement on the Clinical Global Impression scale · patients with depression during opioid agonist treatment for opioid dependence
The intervention probably leads to higher severity of depression dichotomous measures ‐ Tricyclics versus… (moderate certainty).
1 finding from 1 review
Intervention not reported
Severity of depression continuous measures ‐ HDRS total score at the end of the treatment: Tricyclics versus placebo · patients with depression during opioid agonist treatment for opioid dependence
1 finding from 1 review
Total number of drop‐outs · patients with opiate dependent adolescents
Buprenorphine detox may leads to higher drop out Number of participants who dropped out from the study compared with buprenorphine maintenance (low certainty).
1 finding from 1 review
Patients with positive urine at the end of treatment Number of participants with urine positive for opiates · patients with opiate dependent adolescents
Buprenorphine detox showed no clear difference in patients with positive urine at the end of treatment Number of… compared with buprenorphine maintenance (low certainty).
1 finding from 1 review
Self‐reported use at 12 months · patients with opiate dependent adolescents
Buprenorphine detox may leads to higher self‐reported use at 12 months compared with buprenorphine maintenance (low certainty).
1 finding from 1 review
Enrolment in addiction treatment at 12 month · patients with opiate dependent adolescents
Buprenorphine detox showed no clear difference in enrolment in addiction treatment at 12 month compared with buprenorphine maintenance (low certainty).
1 finding from 1 review
Total number of drop‐outs
Buprenorphine maintenance may leads to lower drop‐outs Number of participants who did not complete the study compared with buprenorphine detoxification (low certainty).
1 finding from 1 review
Use of Primary Substance
Buprenorphine maintenance showed no clear difference in use of primary substance Patients with positive urine test at the… compared with buprenorphine detoxification (low certainty).
1 finding from 1 review
Self reported use at 12‐month
Buprenorphine maintenance may leads to lower self reported use at 12‐month compared with buprenorphine detoxification (low certainty).
1 finding from 1 review
Enrolment in addiction treatment at 12 month
Buprenorphine maintenance showed no clear difference in enrolment in addiction treatment at 12‐month compared with buprenorphine detoxification (low certainty).
1 finding from 1 review
Mean days in treatment · Adults with opioid dependence
1 finding from 1 review
Number completing withdrawal treatment · Adults with opioid dependence
Buprenorphine showed no clear difference in completion of withdrawal treatment compared with methadone (moderate certainty).
1 finding from 1 review
Peak withdrawal score · Adults or adolescents with opioid dependence
It is very uncertain whether buprenorphine changes mean peak withdrawal score, compared with alpha2‐adrenergic agonists (very low certainty).
1 finding from 1 review
Mean overall withdrawal score (participant rated) · Adults or adolescents with opioid dependence
Buprenorphine showed no clear difference in mean overall withdrawal score, with various methods of assessment compared with alpha2‐adrenergic agonists (moderate certainty).
1 finding from 1 review
Mean days in treatment (with varying scheduled duration) · Adults or adolescents with opioid dependence
Buprenorphine probably leads to higher mean days in treatment (with varying scheduled duration) compared with alpha2‐adrenergic agonists (moderate certainty).
1 finding from 1 review
Number experiencing adverse effects · Adults or adolescents with opioid dependence
It is very uncertain whether buprenorphine changes number experiencing adverse effects compared with alpha2‐adrenergic agonists (very low certainty).
1 finding from 1 review